HSIC · Q1 2026 Earnings

Q: Cadence and timing of cost savings realization from value creation program; when does program break even on P&L; quarterly cadence of savings realization

G&A cost savings were relatively nominal in Q1 due to offsetting program costs and savings. Acceleration of savings expected Q2 onwards, with back-half 2026 showing significantly better earnings than front-half driven by G&A reductions and gross profit optimization benefits. No specific quarterly breakdown provided.

Cautious

Henry Schein

Reported May 5, 2026

30-second summary

Henry Schein reported Q1 FY2026 revenue of $3.37B (+6.3% YoY) and non-GAAP EPS of $1.32, with all five segments growing and Global Dental up 9.0% — yet management reaffirmed FY2026 sales growth guidance of 3–5% and non-GAAP EPS of $5.23–$5.37 unchanged, implying meaningful deceleration through the rest of the year. New CEO Fred Lowery personally committed to the $125M operating income run-rate by year-end 2026 (en route to >$200M), converting what had been a corporate target into a CEO accountability metric. The Q1 print clears the bar; the guidance choice says management does not yet trust it to persist.

Headline numbers

EPS

Q1 FY2026

$1.32

Revenue

Q1 FY2026

$3.37B

+6.3% YoY

Gross margin

Q1 FY2026

31.8%

Operating margin

Q1 FY2026

5.4%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$3.37B	+6.3%	$3.44B	-2.0%
EPS	$1.32	—	$1.34	-1.5%
Gross margin	31.8%	—	30.9%	+90bps
Operating margin	5.4%	—	4.7%	+70bps

Guidance

Henry Schein reaffirms FY2026 guidance (3–5% sales growth, $5.23–$5.37 non-GAAP EPS) following solid Q1 execution with 6.3% YoY revenue growth and 6.1–9% segment growth.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q1 FY2026	No explicit Q1 guide provided	$3.368B	In-line with YoY growth expectations	Met

Reaffirmed unchanged this quarter: Non-GAAP EPS ($5.23 to $5.37), Total Sales Growth (3% to 5% over 2025), Adjusted EBITDA Growth (mid-single digits vs 2025)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Global Distribution and Value-Added Services	$2.839B	+6.1%
Global Specialty Products	$0.397B	+8.1%
Global Technology	$0.173B	+7.0%
Global Dental	$1.766B	+9.0%
Global Medical	$1.073B	+1.7%
Global Dental Distribution Merchandise Growth	9.0%	—
Global Dental Distribution Equipment Growth	8.6%	—
Global Value-Added Services Growth	10.6%	—
Global Medical Distribution Growth	1.7%	—

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Internal Sales Growth	2.5%
Adjusted EBITDA	$289M
Share Repurchases	1.6M shares at $77.64
Acquisition Intangible Amortization (pre-tax)	$45M

Management tone

Cyber-recovery reset → Strategic outsourcing & CEO transition → Momentum regained with $200M target → CEO personal accountability for $125M

The $200M operating income target has been re-anchored to the CEO's personal credibility. Three quarters ago the consultant-led workstream was unquantified; two quarters ago it landed as "$200M over the next few years"; last quarter Ron specified "over $125M by end of 2026" with 2027 deferred. This quarter, the new CEO took ownership directly: "I am committing to the company's goal of achieving greater than $200 million of annual operating income improvement within the next few years, with a $125 million run rate by the end of 2026." That is a deliberate shift from a corporate target to a leadership commitment, and it raises the cost of any miss disproportionately.

Margin gains are now defensive, not organic. Last quarter the gross margin recovery to 30.9% read as the structural pressure stabilizing. This quarter Ron framed the +28bps YoY non-GAAP operating margin lift with an immediate qualifier: "We have implemented a number of measures designed to offset the potential financial impact of rising oil prices at this time." That hedge — a category of risk that did not appear in prior-quarter framing — recasts the margin print as contingent on cost-mitigation execution rather than operating leverage. The Q&A confirmed the same: management would not quantify oil-price sensitivity beyond saying mitigation plans exist and a "tipping point" exists somewhere above current levels.

AI rhetoric has hardened from concept to operating model. Three quarters ago digital was generic; two quarters ago AI was experimental; last quarter the AWS/Dentrix Ascend partnership and ImageVerify product launches added specificity. This quarter Lowery framed AI as a transformational lever: "our customers are ready to embrace these tools and that Henry Schein is well positioned to lead that transition." The hedging is in the phrase "well positioned to lead" rather than "leading" — but the trajectory across four quarters is unmistakably toward AI as core strategy, not adjunct.

Market share language has shifted from "we are gaining" to "we need to translate." Q3 FY2025 carried the line "the distribution part of Henry Schein has gained momentum. It's back in its stride. We're winning." This quarter Lowery reframed: he intends to "translate our market strength into accelerated growth and improved financial results." The implicit admission is that the share gains have not yet flowed into commensurate earnings — an underexecution thesis the new CEO is taking on as his personal mandate. This is a more candid framing than the prior "winning" rhetoric and explains why guidance was held despite a 6.3% revenue print.

Point-of-care diagnostics has been promoted from background noise to disclosed volatility. Ron's quantification — "lower sales of point-of-care diagnostic test products related to respiratory illness as a result of the light flu season. This category represents roughly 15 to 20% of our medical business" — is the first time this category's size and weather-sensitivity have been sized in available disclosure. Naming the volatility signals it will recur as an explanatory variable in subsequent quarters; medical segment growth is now structurally noisier than the dental side.

Recurring themes management leaned on this quarter:

AI and technology-driven competitive differentiationValue creation initiatives with specific 2026 targets ($125M run rate)Market share gains in dental, pressure in diagnosticsOperational efficiency and agility under new leadershipHigh-growth specialty products approaching 50% of operating incomeE-commerce platform rollout and digital transformation

Risks management surfaced:

Volatility in point-of-care diagnostic test products (15-20% of medical business) tied to seasonal illnessRising oil prices impacting freight costs and product pricingForeign currency exchange rate fluctuationsPotential tariff impactsDigital equipment softness from new market entrants and lower ASPs in scanners/3D printersExecution risk on value creation programs weighted to H2 2026

Q&A highlights

Jason Bednar · Piper Sandler

Gross margin drivers in Q1 and persistence through the year; impact of rising oil prices on margins; specific sensitivity to oil prices above $100-$110/barrel; oil price assumptions embedded in guidance

Gross margin improvement of 25 bps YoY and 86 bps vs Q4 driven by value creation benefits, dynamic pricing, own-brand product growth, and supplier cost management. Management monitoring oil impact but states current mitigation plans can offset increases; guidance assumes ability to mitigate rising costs but acknowledges a tipping point exists. No specific oil price sensitivity provided.

Gross margin improvement: 25 bps YoY, 86 bps vs Q4Own-brand products growing faster with better marginsNo material oil price impact seen yetMitigation plans in place but no quantified sensitivities disclosed

Jeff Johnson · Bayard

How does Henry Schein achieve sustainable upper single to low double-digit EPS growth without episodic restructuring programs; how to build continuous improvement muscle memory

Fred emphasized value creation is not one-off but builds lasting capability (gross profit programs, own-brand initiatives). Strategy includes developing continuous improvement processes, reinvesting cost savings into growth areas like Henry Schein One AI, and leveraging high-growth/high-margin products approaching 50% of operating income by 2027.

High-growth/high-margin products approaching 50% of operating incomeTarget of 50% operating income from high-margin products by end of 2027Investing in AI capabilities through Henry Schein One$200M total value creation target, $125M run rate by year-end 2026

Daniel Grosslight · Citi

Decomposition of dental merchandise growth between market recovery vs. market share gains; visibility into sustainability of momentum

U.S. dental merchandise growth >4% attributed to both modest market improvement and clear market share gains via internal data. Strong international pockets (Brazil, Canada) also driven largely by share gains. Management sees market as still relatively low-growth but company taking share.

U.S. dental merchandise internal growth >4%Modest positive tone in U.S. market but still relatively low growth overallData indicates market share gains in multiple geographiesStrong growth in Brazil and Canada outside U.S.

Glenn Santangelo · Barclays

Sequential quarterly performance in Q1; impacts from weather, flu season, war in March; early visibility into April performance

March stronger than February sequentially; softness in Q1 driven primarily by light flu season affecting respiratory business rather than weather. April continues strong momentum. Medical segment had seasonal softness.

Sequential improvement through Q1 (February < March)Respiratory/flu season impact was primary headwind, not weatherApril momentum remains strongMedical segment softness attributable to light flu season

Kevin Caliendo · UBS

Cadence and timing of cost savings realization from value creation program; when does program break even on P&L; quarterly cadence of savings realization

G&A cost savings were relatively nominal in Q1 due to offsetting program costs and savings. Acceleration of savings expected Q2 onwards, with back-half 2026 showing significantly better earnings than front-half driven by G&A reductions and gross profit optimization benefits. No specific quarterly breakdown provided.

Q1 impact relatively nominal (program costs offset savings)Savings acceleration beginning Q2, accelerating further Q3-Q4Back-half 2026 earnings expected materially better than front-halfGross profit benefits also expected to accumulate through year

Answers to last quarter's watch list

H1 2026 EPS YoY direction — Q1 non-GAAP EPS came in at $1.32, comparing favorably against management's H2-weighted framing. The print, combined with reaffirmed FY guidance of $5.23–$5.37, removes the risk that H1 EPS materially undershoots and forces the H2 bridge into stretch territory.

Resolved positively

Sales growth vs the 3–5% range — Reported total sales growth was 6.3% YoY, above the FY top end; internal sales growth came in at 2.5%. The FY 3–5% range is a total sales growth guide (not internal), so the 6.3% print clears it, while the 2.5% internal figure is a separate read on organic momentum running below the headline. Management held guidance rather than raising, signaling caution about persistence. Status: Mixed

$125M value creation run-rate tracking — Management did not provide a Q1 dollar booking against the $125M target. Per UBS Q&A, Q1 impact was "relatively nominal" with program costs offsetting savings, and acceleration is back-half-loaded. This is closer to the worst-case configuration flagged last quarter (back-end loaded raises execution risk) and management still won't provide quarterly specificity.

Continue monitoring

Specialty Products growth normalization — Specialty grew 8.1%, landing at the top of management's stated 5–8% durable rate — moderating from Q4's 14.6% as guided but holding the upper bound. This is the constructive normalization path.

Resolved positively

Distribution gross margin trajectory — Consolidated gross margin printed 31.8%, well above the 30.5% threshold from the watch and above Q4's 30.9% by 86bps QoQ. The structural-pressure question from Q4 has resolved favorably for one quarter, though Q&A made clear margin sustainability now hinges on oil-cost mitigation execution.

Resolved positively

Adjusted EBITDA growth quantification — Management reaffirmed "mid-single digits" without quantifying — the third consecutive guide using identical qualitative language. The pattern is now structural: EBITDA growth framing is being deliberately held vague even as EPS guidance is specific, confirming the EPS lift continues to depend on buybacks, tax, and interest rather than operating leverage.

Resolved negatively

What to watch into next quarter

Internal sales growth trajectory — Q1 internal sales growth was 2.5%, well below the 6.3% total sales growth headline. Watch whether Q2 internal sales accelerates above 3% (validating organic momentum) or stays flat-to-soft (suggesting the headline is increasingly dependent on FX and acquisitions to clear the FY total sales growth range).

Value creation program dollar booking in Q2 — Management said Q1 was "relatively nominal" with acceleration from Q2 onward. Watch for explicit Q2 commentary quantifying how much of the $125M run-rate is realized. Anything short of ~$30M of run-rate by Q2 leaves the back-half requirement at $60M+, which compresses Q3 and Q4 execution windows materially.

Medical segment growth ex-diagnostics — POC diagnostics is now sized at 15–20% of medical. Watch whether Q2 medical growth recovers to the +4–5% range (signaling Q1's +1.7% was flu-season noise) or stays sub-3% (suggesting broader medical pressure beyond diagnostics).

Gross margin direction with oil pass-through — Q1 gross margin of 31.8% was the strongest in recent quarters but Q&A flagged oil/freight cost pressure ahead. Watch whether Q2 gross margin holds above 31.0% (mitigation working) or compresses toward 30.5% (tipping point reached). A drop below 30.5% would invalidate the recovery thesis.

EBITDA growth quantification — "Mid-single digits" language has now persisted across three consecutive guides. Watch whether Q2 brings the first quantified EBITDA range — that would be a much stronger operating-leverage signal than continued EPS-only guidance pinned by buybacks.

AI product disclosure progression — Q1 added rhetorical commitment ("well positioned to lead") but no new product-level disclosures beyond pipeline expansion. Watch Q2 for named AI product revenue contribution, attach rates, or subscriber metrics that convert AI rhetoric into measurable contribution to the high-growth/high-margin mix.

Sources

Henry Schein Q1 FY2026 press release, Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/1000228/000100022826000021/exhibit991.htm
Henry Schein Q1 FY2026 earnings conference call, May 5, 2026 (prepared remarks and Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.